Ann: P2 trial shows significant improvements in Phelan-McDermid, page-133

Almost 11 years ago exactly (Dec 19, 2012) I bought my first holding of NEU, @.094 each. It was in my SMSF and I've been a holder ever since and added to it somewhat cautiously over the years, my confidence growing as the results started coming in. It was risky back then, and it's been a long road but most biotechs fail, so full kudos to Neuren's team. I'm not making any predictions, just wanted to say thanks for all the posters here, for the most part they are polite and the posts are worth reading, unlike for some other stocks. Congratulations to all holders who like me, went from being speculators to believers, and to the company for bringing a much-needed drug to a market that has been largely ignored by big pharma.